Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "PhRMA" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about PhRMA for you to read. Along with our medical data and news we also list PhRMA Clinical Trials, which are updated daily. BioPortfolio also has a large database of PhRMA Companies for you to search.
In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters introduced the 340B PAUSE Act, and just this week, Sena
Yesterday, PhRMA submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) Request for Information (RFI) on sharing a portion of manufacturer rebates directly with beneficiaries at the point of sale.
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary milestone for the biopharmaceutical industry and
You may have recently read about how biopharmaceutical companies and insurers are working together to implement new approaches to paying for medicines, including through results-based contracts (RBCs), which link reimbursement to real
Last month, we released a State of Vaccines report, as well as an update to our Medicines in Development for Vaccines report, which shared exciting information about the 264 vaccines currently in development by America’s biopharmaceutical companies. These include vaccines for
According to new data from the National Health Expenditures (NHE), retail medicine spending grew just 1.3 percent in 2016, down from 9 percent in 2015. To put that in context, total spending for hospitals grew more than 3.5 times that amount. This data, recently published in Health Affairs, reaffirms how our nation’s competitive marketplace for medicines controls costs while supporti...
The number of Americans affected by Alzheimer’s disease (AD) continues to rise according to a new report.1 Researchers found that approximately 6.08 million Americans had Alzheimer’s or mild
Both payers and providers are interested in additional information from biopharmaceutical companies about prescription medicines – including information about pipeline medicines and unapproved uses of approved medicines. This finding is from a recent survey of payer executives and specialty physicians conducted by Health Strategi
Today marks World AIDS Day, a moment to reflect on the significant advances made in the treatment and prevention of HIV, the virus which causes AIDS. The incredible scientific progress biopharmaceutical companies have made in the last 30 years has led to an 88 percent decline in the
Stakeholders are gathering in London this week for a workshop entitled Data Anonymization – a Key Enabler for Clinical Data Sharing. The workshop, jointly organized by the European Medicines Agency (EMA) and the Multi-Regional Clinical Trials Center of Brigham and
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no ...
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into the marketplace. Thanks in part to the incentives in the law, 90 percent of prescriptions today are filled with generi
A recent IHS Markit report, “The Clinical and Economic Benefits of Better Treatment of Adult Medicaid Beneficiaries with Diabetes,” simulated savings in the Medicaid program as a result of better management of diabetes. The study found that controlling blood pressure, total
Today, PhRMA submitted its comments in response to the Centers for Medicare & Medicaid Services (CMS) request for information on the future of the Center for Medicare and Medicaid Innovation (CMMI). While well intentioned, CMMI’s current flexibility to make far-reaching changes has raised a number of concerns about large-scale mandatory demonstrations developed without stakeholde...
Perhaps the biggest fact that is often overlooked about Part D is that there is already significant price negotiation in the program. Thanks to Part D’s competitive structure, large purchasers often negotiate steep discounts and rebates with prescription drug man
New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies are working with insurers to develop new ways to pay for medicines.
In honor of Veterans Day, we spoke with Rob Caskey, a senior manager in PhRMA’s finance department about his military service, journey to PhRMA and why veterans make great employees for America’s biopharmaceutical companies.
Today, leading minds will come together for an in-depth conversation centered on vaccines – their critical role in warding off disease, the innovative science powering breakthroughs in their research and what their future might look like.
The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment. Next week, on Wednesday, November 8, leading minds in the fight against cancer will come together in Philadelphia for a conversation led by Axios titled, “Future Shapers: A New Era in Cancer Care.” The event is sponsored as part of Ph...
In case you missed it, earlier this month, the Center for Medicare & Medicaid Services formally withdrew a controversial proposal that would have had a detrimental impact on patient access to lifesaving treatments covered under Part B,
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study comparing the effectiveness of oral and injectable disease-modifying therapies for patients with multiple sclerosis.
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have taken notice. Just last week, the House Energy and Commerce Subcommittee on Oversight and Investigations held a hearing to examine how the 340B program is being used by 340B covered entitie...
Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its enactment. As stated previously, these claims are unequivocally false and last nig
Today, Lori Reilly, executive vice president for policy, research and membership at the Pharmaceutical Research and Manufacturers of America (PhRMA), testified at the U.S. Senate Committee on Health, Education Labor and Pensions about understanding the role the drug delivery system plays in determining what patients pay for medicines.
Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). The analysis of 20 medicines also found the amount hospitals receive after negotiations with commercial payers is, on average, more than 250 percent what they paid to acquire the ...